|
Vitruvia Medical AG / Key word(s): Annual Results/Annual Report Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023 25-Jun-2023 / 09:59 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023 Anglikon, June 25, 2023: Vitruvia Medical AG reported net income after taxes of CHF -1,095,349.38 for the year ended December 31, 2022, compared to CHF -8,002,497.53 in the previous year. On a consolidated basis, Vitruvia Medical AG generated revenues of EUR 1,525,529.– and operating earnings before interest, taxes, depreciation and amortization (EBITA) of EUR -912,086. Earnings after taxes amount to EUR -1,484,556 compared to the previous year of EUR -8,131,520.00. Outlook 2023 For the current year, Vitruvia Medical AG and its subsidiary LT technologies GmbH & Co. KG to generate revenues of approximately EUR 1.8 million and earnings (before interest, taxes, depreciation and amortization) of approximately EUR 304,000 (unconsolidated). On a consolidated basis, Vitruvia Medical AG expects a further improvement in earnings compared to the previous year, which will, however, still be in negative territory. About Vitruvia Medical AG: Vitruvia Medical AG is a Swiss investment company focused on the repair, production and trade of medical devices as well as surgical instruments. Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success. Vitruvia Medical AG Markus A. Bertschin President of the Board of Directors Kesselackerstrasse 18 CH-5611 Anglikon End of Inside Information 25-Jun-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Prenatal exposure to phthalates linked to higher risk of preterm birth and low birth weight
Research in The Lancet Planetary Health links prenatal phthalate exposure to increased risks of preterm birth and low birth weight, underscoring the need for regulatory
February 12, 2024